Oxitropium bromide (Ba253BINEB) vs Umeclidinium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Oxitropium bromide (Ba253BINEB)

Developed by Boehringer Ingelheim

Phase 3 in Asthmasmall molecule
Weak signal

NCT02182661 · Phase 3 · completed

The study was an open-label, single-arm trial of 88 participants with no randomization or comparator group. Its primary outcomes were safety measures, but no results were posted, so there is no reported primary-endpoint comparison to assess.

No aligned efficacy figure on record for this race.

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Phase 2 in Asthmasmall molecule
Partial signal

NCT01573624 · Phase 2 · completed

The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.

Reported efficacy

Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)

Result source: NCT01573624

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOxitropium bromide (Ba253BINEB)Umeclidinium
Severe exacerbations, annualised rate—Not posted · NCT02182661—Trial running · NCT04651777
Trough FEV1, change—Not posted · NCT021826610.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
ACQ-5, change—Not posted · NCT02182661—Trial running · NCT04651777
OCS dose reduction—Not posted · NCT02182661—Trial running · NCT04651777

Severe exacerbations, annualised rate

Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661
Umeclidinium
—Trial running · NCT04651777

Trough FEV1, change

Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661
Umeclidinium
0.3 vs 0.1+0.2 vs placebo31.25 mcg QD · wk 24 · n 136NCT03012061
17 other results
  • 0.1 vs 0.0 31.25 µg QD · wk 2 · n 124 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 31.25 µg BID · wk 2 · n 118 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 250 µg QD · wk 2 · n 117 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 125 µg QD · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.3 vs 0.1 62.5 mcg QD · wk 24 · n 139 · Phase 2 · primary NCT03012061
  • 0.1 vs 0.0 62.5 µg QD · wk 2 · n 122 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg QD · wk 2 · n 120 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.0 15.6 µg BID · wk 2 · n 113 · Phase 2 · primary NCT01641692
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.2 100 mcg + 15.6 mcg · wk 2 · n 154 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 31.25 mcg · wk 2 · n 146 · Phase 2 · primary NCT01573624
  • 0.1 vs 0.2 100 mcg + 62.5 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 125 mcg · wk 2 · n 155 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.2 100 mcg + 250 mcg · wk 2 · n 150 · Phase 2 · primary NCT01573624
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539

ACQ-5, change

Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661
Umeclidinium
—Trial running · NCT04651777

OCS dose reduction

Oxitropium bromide (Ba253BINEB)
—Not posted · NCT02182661
Umeclidinium
—Trial running · NCT04651777
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Oxitropium bromide (Ba253BINEB): no structured comparison results are available for Asthma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Oxitropium bromide (Ba253BINEB): 0 of 4 rows · Umeclidinium: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricUmeclidinium
Dropout rate
—100 mcg + 125 mcga
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
5.9%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
5.1%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
6.5%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
5.8%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—100 mcg + 125 mcga
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
—100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
—100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%100 mcg + 125 mcga
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 19 more results
0%100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.6%100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0%31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
—31.25 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.7%250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%31.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0%15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.9%31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
2.2%62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
100 mcg + 125 mcga
headache 2.3%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 18 more results
100 mcg + 15.6 mcg
headache 2.2%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 250 mcg
headache 3.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 31.25 mcg
headache 1.1%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
100 mcg + 62.5 mcg
headache 2.8%
NCT01573624 · Phase 2 · combination · Asthma · phase 2
31.25 µg BID
headache 4.5% (placebo 1.6%)
nasopharyngitis 1.5% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
250 µg QD
headache 4.4% (placebo 1.6%)
product taste abnormal 3.7% (placebo 0%)
nasopharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
125 µg QD
headache 3.1% (placebo 1.6%)
product taste abnormal 3.1% (placebo 0%)
nasopharyngitis 2.3% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
62.5 µg QD
headache 3.8% (placebo 1.6%)
pharyngitis 3.8% (placebo 0.8%)
nasopharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.5 µg QD
headache 2.9% (placebo 1.6%)
product taste abnormal 1.4% (placebo 0%)
pharyngitis 0.7% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg BID
nasopharyngitis 3.2% (placebo 0.8%)
headache 1.6% (placebo 1.6%)
pharyngitis 0.8% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
15.6 µg QD
headache 3.8% (placebo 1.6%)
nasopharyngitis 2.3% (placebo 0.8%)
pharyngitis 0% (placebo 0.8%)
NCT01641692 · Phase 2 · combination · Asthma · phase 2
31.25 mcg QD
nasopharyngitis 10.1% (placebo 11.9%)
headache 6.5% (placebo 7.7%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
62.5 mcg QD
nasopharyngitis 9.4% (placebo 11.9%)
headache 8.6% (placebo 7.7%)
upper respiratory tract infection 4.3% (placebo 2.1%)
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Umeclidinium

FEV1 Trough 0.026 L @ 2wk100 mcg + 15.6 mcg
absolute change · L
No placebo or comparator arm
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
0.032 L @ 2wk100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0385 L @ 2wk100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.0444 L @ 2wk100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.051 L @ 2wk100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
FEV1 Trough 0.076 vs 0.046 placebo L @ 2wk31.25 µg QD
absolute change · L
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 17 more results
0.097 vs 0.046 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.3046 vs 0.1289 placebo L @ 24wk31.25 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.057 vs 0.046 placebo L @ 2wk250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.143 vs 0.047 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.134 vs 0.046 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.175 vs 0.047 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.145 vs 0.12 FF L @ 2wk100 mcg + 15.6 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.152 vs 0.12 FF L @ 2wk100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.145 vs 0.12 FF L @ 2wk100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.174 vs 0.12 FF L @ 2wk100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.175 vs 0.12 FF L @ 2wk100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
0.146 vs 0.047 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.193 vs 0.047 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.08 vs 0.046 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.313 vs 0.1289 placebo L @ 24wk62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
0.112 vs 0.046 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.103 vs 0.046 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Morning PEF 13 vs -2.9 FF L100 mcg + 15.6 mcg
absolute change · L
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
14.5 vs -2.9 FF L100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
15.7 vs -2.9 FF L100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
20 vs -2.9 FF L100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
19 vs -2.9 FF L100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
Evening PEF 11.1 vs -5.2 FF L/min100 mcg + 15.6 mcg
absolute change · L/min
NCT01573624 · Phase 2 · combination · Asthma · phase 2
show 4 more results
12.1 vs -5.2 FF L/min100 mcg + 31.25 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
16 vs -5.2 FF L/min100 mcg + 62.5 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
23.7 vs -5.2 FF L/min100 mcg + 125 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
17.7 vs -5.2 FF L/min100 mcg + 250 mcg
NCT01573624 · Phase 2 · combination · Asthma · phase 2
FEV1 Wm0 24 h 0.077 vs -0.025 placebo L @ 2wk31.25 µg QD
absolute change · L
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
0.043 vs -0.025 placebo L @ 2wk31.25 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.048 vs -0.025 placebo L @ 2wk250 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.094 vs -0.025 placebo L @ 2wk125 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.092 vs -0.025 placebo L @ 2wk62.5 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.06 vs -0.025 placebo L @ 2wk15.6 µg QD
NCT01641692 · Phase 2 · combination · Asthma · phase 2
0.097 vs -0.025 placebo L @ 2wk15.6 µg BID
NCT01641692 · Phase 2 · combination · Asthma · phase 2
Evening PEF Change L/Min 1.5 vs -5.1 placebo L/min @ 2wk31.25 µg QD
absolute change · L/min
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
show 6 more results
8.7 vs -5.1 placebo L/min @ 2wk31.25 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.3 vs -5.1 placebo L/min @ 2wk250 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
9.8 vs -5.1 placebo L/min @ 2wk125 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
-0.9 vs -5.1 placebo L/min @ 2wk62.5 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
10 vs -5.1 placebo L/min @ 2wk15.6 µg QD
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
2.5 vs -5.1 placebo L/min @ 2wk15.6 µg BID
PM, n=116, 123, 123, 119, 115, 118, 108, 121
NCT01641692 · Phase 2 · combination · Asthma · phase 2
FEV1 Change 3 h 0.3663 vs 0.1768 placebo L @ 24wk31.25 mcg QD
absolute change · L
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
show 5 more results
0.052 vs 0.048 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.072 vs 0.048 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.093 vs 0.048 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.088 vs 0.048 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.3744 vs 0.1768 placebo L @ 24wk62.5 mcg QD
NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy
Rescue Puffs -0.2 vs 0.6 FF Puffs @ 4wk100/250 µg
absolute change · Puffs
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
0 vs 0.6 FF Puffs @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.4 vs 0.6 FF Puffs @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-0.5 vs 0.6 FF Puffs @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Total -1.5 vs 0.5 FF score @ 4wk100/250 µg
absolute change · score
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Morning PEF 10.5 vs -14.2 FF L/min @ 4wk100/250 µg
absolute change · L/min
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
show 3 more results
5.5 vs -14.2 FF L/min @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
3.9 vs -14.2 FF L/min @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
7.6 vs -14.2 FF L/min @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxitropium bromide (Ba253BINEB)'s landscape · Umeclidinium's landscape